{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:47:48Z","timestamp":1788558468424,"version":"build-2803163510"},"reference-count":20,"publisher":"American Society of Hematology","issue":"8","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,22]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by complement pathway-mediated hemolysis. Riliprubart (SAR445088, BIVV020), a second-generation classical complement inhibitor, is a humanized monoclonal antibody that selectively inhibits only the activated form of C1s. This Phase 1b study evaluated the safety, tolerability, and effect on hemolysis of riliprubart in adult patients with cold agglutinin disease. On day 1, 12 patients received a single IV dose of either 30 mg\/kg (n = 6) or 15 mg\/kg (n = 6) of riliprubart and were subsequently followed for 15 weeks. Riliprubart was generally well tolerated; there were no treatment-emergent serious adverse events, or treatment-emergent adverse events leading to death or permanent study discontinuation. There were no reports of serious infections, encapsulated bacterial infections including meningococcal infections, hypersensitivity, or thromboembolic events. Rapid improvements in hemoglobin (day 5) and bilirubin (day 1) were observed in both treatment cohorts. Mean hemoglobin levels were maintained at &amp;gt;11.0 g\/dL from day 29 and mean levels of bilirubin were normalized by day 29; both responses were maintained throughout the study. Improvements in clinical markers closely correlated with a sustained reduction in the 50% hemolytic complement (CH50) throughout the study. Mean C4 levels, an in\u00a0vivo marker of treatment activity, increased 1 week after treatment with either dose of riliprubart and were sustained throughout the study. In conclusion, a single IV dose of riliprubart was well tolerated, and led to rapid classical complement inhibition, control of hemolysis, and improvement in anemia, all of which were sustained over 15 weeks. This trial was registered at www.ClinicalTrials.gov as #NCT04269551.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023022153","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T19:13:10Z","timestamp":1702408390000},"page":"713-720","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0840-3499","authenticated-orcid":false,"given":"Shirley","family":"D\u2019Sa","sequence":"first","affiliation":[{"name":"1UCLH Centre for Waldenstr\u00f6m\u2019s Macroglobulinaemia and Related Conditions, University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3229-9556","authenticated-orcid":false,"given":"Josephine M. I.","family":"Vos","sequence":"additional","affiliation":[{"name":"2Amsterdam University Medical Center, University of Amsterdam, and Sanquin, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Barcellini","sequence":"additional","affiliation":[{"name":"3Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Ward\u0119cki","sequence":"additional","affiliation":[{"name":"4Sanofi, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Perrin","sequence":"additional","affiliation":[{"name":"5Sanofi, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Barker","sequence":"additional","affiliation":[{"name":"6Sanofi, Chilly-Mazarin, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Zilberstein","sequence":"additional","affiliation":[{"name":"7Sanofi, Bridgewater, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Storek","sequence":"additional","affiliation":[{"name":"8Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Chow","sequence":"additional","affiliation":[{"name":"8Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-7699","authenticated-orcid":false,"given":"Alexander","family":"R\u00f6th","sequence":"additional","affiliation":[{"name":"9Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2024022216263064300_bib1","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"issue":"3","key":"2024022216263064300_bib2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.seminhematol.2018.04.002","article-title":"Complement activation and inhibition in autoimmune hemolytic anemia: focus on cold agglutinin disease","volume":"55","author":"Berentsen","year":"2018","journal-title":"Semin Hematol"},{"key":"2024022216263064300_bib3","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3389\/fimmu.2020.00590","article-title":"New insights in the pathogenesis and therapy of cold agglutinin-mediated autoimmune hemolytic anemia","volume":"11","author":"Berentsen","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"2024022216263064300_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3390\/hemato3010014","article-title":"Cold agglutinin disease: a distinct clonal B-cell lymphoproliferative disorder of the bone marrow","volume":"3","author":"Climent","year":"2022","journal-title":"Hemato"},{"issue":"4","key":"2024022216263064300_bib5","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.2020005674","article-title":"Cold agglutinin disease revisited: a multinational, observational study of 232 patients","volume":"136","author":"Berentsen","year":"2020","journal-title":"Blood"},{"issue":"13","key":"2024022216263064300_bib6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/bloodadvances.2017004390","article-title":"Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization","volume":"1","author":"Mullins","year":"2017","journal-title":"Blood Adv"},{"issue":"3","key":"2024022216263064300_bib7","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.14478","article-title":"The diagnosis and management of primary autoimmune hemolytic anemia","volume":"176","author":"Hill","year":"2017","journal-title":"Br J Haematol"},{"issue":"12","key":"2024022216263064300_bib8","doi-asserted-by":"crossref","first-page":"e0276617","DOI":"10.1371\/journal.pone.0276617","article-title":"Medically-attended anxiety and depression is increased among newly diagnosed patients with cold agglutinin disease: analysis of an integrated claim-clinical cohort in the United States","volume":"17","author":"Broome","year":"2022","journal-title":"PLoS One"},{"issue":"9","key":"2024022216263064300_bib9","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1182\/blood.2021014955","article-title":"Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial","volume":"140","author":"R\u00f6th","year":"2022","journal-title":"Blood"},{"issue":"14","key":"2024022216263064300_bib10","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"R\u00f6th","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"2024022216263064300_bib11","unstructured":"Enjaymo. Prescribing information. Sanofi; 2023. Accessed 1 October 2023. https:\/\/products.sanofi.us\/enjaymo\/enjaymo.pdf."},{"key":"2024022216263064300_bib12","unstructured":"Sanofi\n          . FDA Approves EnjaymoTM (Sutimlimab-Jome), First Treatment for Use in Patients With Cold Agglutinin Disease. Accessed 1 October 2023. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2022\/2022-02-04-22-00-00-2379517."},{"key":"2024022216263064300_bib13","unstructured":"Sanofi\n          . European Commission Approves Enjaymo\u00ae (Sutimlimab) for Treatment of Hemolytic Anemia in Adult Patients With Cold Agglutinin Disease. Accessed 1 October 2023. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2022\/2022-11-17-17-50-00-2558583."},{"key":"2024022216263064300_bib14","unstructured":"Sanofi\n          . SwissMedic. Enjaymo\u00ae Authorization. Accessed 1 October 2023. https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/humanarzneimittel\/authorisations\/new-medicines\/enjaymo-inflsg-sutimlimabum.html#."},{"key":"2024022216263064300_bib15","unstructured":"Sanofi\n          . MFDS South Korea authorization NJMOJU (sutimlimab) Ministry of Food and Drug Safety Drug Integrated Information System Detailed View of Drug Product Information (NJ Moju (Sutimlimab)). Accessed 1 October 2023. https:\/\/nedrug.mfds.go.kr\/pbp\/CCBBB01\/getItemDetailCache?cacheSeq=202302142aupdateTs2023-08-12%2008:10:36.77738b."},{"issue":"4","key":"2024022216263064300_bib16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/cts.13481","article-title":"First-in-human study with SAR445088: a novel selective classical complement pathway inhibitor","volume":"16","author":"Chow","year":"2023","journal-title":"Clin Transl Sci"},{"key":"2024022216263064300_bib17","doi-asserted-by":"crossref","first-page":"109629","DOI":"10.1016\/j.clim.2023.109629","article-title":"Anti-C1s humanized monoclonal antibody SAR445088: a classical pathway complement inhibitor specific for the active form of C1s","volume":"251","author":"Simmons","year":"2023","journal-title":"Clin Immunol"},{"issue":"7","key":"2024022216263064300_bib18","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1080\/19420862.2019.1633883","article-title":"Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life","volume":"11","author":"Mackness","year":"2019","journal-title":"MAbs"},{"issue":"suppl 3","key":"2024022216263064300_bib19","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.1186\/ar586","article-title":"Complement and systemic lupus erythematosus","volume":"4","author":"Walport","year":"2002","journal-title":"Arthritis Res"},{"key":"2024022216263064300_bib20","unstructured":"Sanofi\n          . Enjaymo. Summary of product characteristics. Accessed 1 October 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enjaymo-epar-product-information_en.pdf."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/8\/713\/2214969\/blood_bld-2023-022153-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/8\/713\/2214969\/blood_bld-2023-022153-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T16:26:59Z","timestamp":1708619219000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/8\/713\/506604\/Safety-tolerability-and-activity-of-the-active-C1s"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,2,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022153","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]}}}